Examples of commercial molecular diagnostic assays for the detection of SARS-CoV-2a.
Manufacturer | Test name | Method | Target gene | Specimen type | LODb | Sensitivity | Specificity | Statusc | Ref. |
---|---|---|---|---|---|---|---|---|---|
LumiraDx UK Ltd | LumiraDx SARS-CoV-2 RNA STAR Complete | RT, qSTAR amplification, home collection, screening, pooling | N gene | Nasal swabs | 32 TCID50 per mL | 97% | 96% | H | 36 |
Abbott Molecular Inc. | Abbott RealTime SARS-CoV-2 Assay | RT-PCR | N and RdRP genes | Nasopharyngeal and oropharyngeal swabs | 100 copies per mL | 95.9% | 100% | H | 37 |
Meridian Bioscience, Inc. | Revogene SARS-CoV-2 | RT-PCR | N gene | Nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swab specimens | 7 TCID50 per mL | 97.7% | 97.7% | H, M | 15 |
Talis Biomedical Corporation | Talis One COVID-19 Test System | Reverse transcriptase isothermal amplification | ORF1ab gene, N gene | Nasal mid-turbinate swabs | 500 copies per mL | 100% | 100% | H, M, W | 38 |
Cepheid | Xpert Xpress CoV-2/Flu/RSV plus | rRT-PCR | N gene, E gene, RdRP genes | Nasopharyngeal swabs, anterior nasal swabs, nasal wash/aspirate specimens | 138 copies per mL | 100% | 100% | H, M, W | 39 |
Life Technologies Corporation (a part of Thermo Fisher Scientific Inc.) | TaqPath COVID-19 Fast PCR Combo Kit 2.0 | rRT-PCR | N gene, ORF1a, ORF1b | Saliva | 1000 GCE per mL | 97.1% | 97.6% | H | 40 |
Detect, Inc. | Detect Covid-19 Test | RT-LAMP | ORF1ab | Anterior nasal swabs | 800 copies per mL | 90.9% | 97.5% | Home, H, M, W | 41 |
PerkinElmer, Inc. | PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 | rRT-PCR | N gene, ORF1a gene | Nasopharyngeal swabs, anterior nasal swabs, and mid-turbinate swabs | SARS-CoV-2: 0.11 TCID50 per mL | 100% | 100% | H | 20 |
LMSI, LLC (dba Lighthouse Lab Services) | CovidNow SARS-CoV-2 Assay | rRT-PCR | N gene | Upper respiratory specimens, self-collected anterior nasal swab specimens | 800 copies per mL | 96% | 100% | H | 21 |
Applied DNA Sciences Inc. | Linea COVID-19 Assay Kit | rRT-PCR | S gene (S1 and S2 regions) | Nasopharyngeal swabs and oropharyngeal swabs | 1250 copies per mL | 98% | 92% | H | 22 |
Enzo Life Sciences, Inc. | AMPIPROBE SARS-CoV-2 Test System | rRT-PCR | N gene and RdRP gene | Nasal, mid-turbinate, nasopharyngeal, and oropharyngeal swab specimens | 280 copies per mL | 96.2% | 98% | H | 42 |
Thermo Fisher Scientific Inc. | TaqPath COVID-19 RNase P Combo Kit 2.0 | rRT-PCR | N gene, ORF1a, ORF1b | Nasopharyngeal, anterior, and mid-turbinate nasal swabs | 75 GCE per mL | 96.7% | 95% | H | 43 |
Twist Bioscience Corporation | SARS-CoV-2 NGS Assay | NGS | Several | Nasopharyngeal swabs, oropharyngeal swabs, anterior nasal swabs | 800 copies per mL | 96.7% | 100% | H | 44 |
BioGX, Inc. | BioGX Xfree COVID-19 Direct RT-PCR | rRT-PCR | N1 gene | Nasopharyngeal, anterior nasal, mid-turbinate | 1000–3000 copies per mL (depending on the platform used) | 95% | 100% | H | 26 |
OSANG Healthcare | GeneFinder COVID-19 Plus RealAmp Kit | rRT-PCR | RdRP, E gene, N gene | Alveolar lavage fluid, throat swab, sputum | 10 copies per 20 μL reaction | 100% | 100% | H | 45 |
OPTI Medical Systems | OPTI SARS-CoV-2 RT PCR Test | rRT-PCR, pooling | N gene (N1 and N2) | Anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs | 700–900 copies per mL | 100% | 100% | H | 46 |
PathogenDx, Inc. | DetectX-Rv | rRT-PCR, DNA microarray hybridization | N gene (N1 and N2 regions) | Nasopharyngeal swabs, oropharyngeal swabs, mid-turbinate swabs, anterior nasal swabs | 1000 copies per mL | 95% | 100% | H | 47 |
Hologic, Inc. | Aptima SARS-CoV-2 Assay | Real-time TMA, dual kinetic assay | ORF1ab (2 targets) | Nasopharyngeal, nasal, mid-turbinate, and oropharyngeal swab specimens | 212 copies per mL within a sample (83 copies per mL within the tested aliquot) | 100% | 98% | H | 48 |
LumiraDx UK Ltd | LumiraDx SARS-CoV-2 RNA STAR Complete | RT-qSTAR amplification | ORF1a | Mid-turbinate, nasopharyngeal, and oropharyngeal swabs | 7500 copies per mL | 97.8% | 98.5% | H | 49 |
Quidel Corporation | Solana SARS-CoV-2 Assay | Molecular isothermal Reverse Transcriptase – Helicase-Dependent Amplification (RT-HDA) | ORF1ab | Nasopharyngeal and nasal swab specimens | 1.16 ×104 copies per mL | 90.3% | 97.8% | H, M | 32 |
Cue Health Inc. | Cue COVID-19 Test for Home and Over the Counter Use | Isothermal amplification, home collection | N gene | Anterior nares swabs | 2700 copies per mL | 96% (symptomatic), (100% asymptomatic) | 98% (symptomatic), (100% asymptomatic) | Home, H, M, W | 50 |
Grifols Diagnostic Solutions Inc. | Procleix SARS-CoV-2 Assay | Transcription-mediated nucleic acid amplification (TMA) | Not stated | Anterior nasal and mid-turbinate nasal swabs, nasopharyngeal | 60 copies per mL | 100% | 100% | H | 51 |
Agena Bioscience, Inc. | MassARRAY SARS-CoV-2 Panel | rRT-PCR, MALDI-TOF | N gene (N1, N2, and N3 regions), ORF1, and ORF1ab | Nasopharyngeal swabs, oropharyngeal swabs, nasal and mid-turbinate swabs | 310–2500 copies per mL | 98.9% | 100% | H | 35 |
Cepheid | Xpert® Omni SARS-CoV-2 | rRT-PCR | E gene and N gene (N2 region) | Nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab specimens | 400 copies per mL | 100% | 100% | H, M, W | 52 |
Lucira Health, Inc. | Lucira COVID-19 All-In-One Test Kit | RT-LAMP | N gene (two regions) | Nasal swab (self-collection), nasal swab (healthcare collection) | 2700 copies per swab (or 900 copies per mL if the sample is 100% lysed and eluted) | 94% | 98% | Home, H, M, W | 53 |
GenMark Diagnostics, Inc. | ePlex Respiratory Pathogen Panel 2 | rRT-PCR, electrochemical detection | Not stated | Nasopharyngeal swabs | 0.01TCID50 per mL | 100% | 100% | H, M | 54 |
Seasun Biomaterials, Inc. | AQ-TOP COVID-19 Rapid Detection Kit PLUS | RT-LAMP | ORF1ab and N genes | Oropharyngeal and nasopharyngeal swabs, anterior nasal and mid-turbinate nasal swabs | 1000 copies per mL | 100% | 100% | H | 55 |
Clear Labs, Inc. | Clear Dx SARS-CoV-2 Test | rRT-PCR, NGS | Several | Nasopharyngeal swab, oropharyngeal swab, anterior nasal swab | 2000 copies per mL | 100% | 100% | H | 56 |
Abbott Diagnostics Scarborough | ID NOW COVID-19 | Isothermal amplification | RdRP | Direct nasal secretions, nasopharyngeal or throat swabs | 125 copies per mL | 100% | 100% | H, M, W | 57 |
Cue Health Inc. | Cue COVID-19 Test | Isothermal amplification | N gene | Nasal swab | 1300 copies per mL | 100% | 92% | Home, H, M, W | 58 |
H: laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (chemiluminescence immunoassay, CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests. M: laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate complexity tests. W: patient care settings operating under a CLIA Certificate of Waiver.
LOD, Limit of detection.
Status, Authorized settings include the following.